Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06852963 · ClinicalTrials.gov registry record · Phase 1
A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001
A Phase 1 study of Retinal Disease and Retinal Degeneration, sponsored by PYC Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
- 6
- Study locations
NCT06852963 is a Phase 1 study of Retinal Disease and Retinal Degeneration that is actively recruiting participants, run by PYC Therapeutics. The registered enrollment target is 16 participants, below the 1,240-participant average among 19 other Retinal Disease trials with a reported enrollment target (99% lower). The trial reports 6 study locations across 4 states.
The verdict
NCT06852963, a Phase 1 study of Retinal Disease and Retinal Degeneration, is actively recruiting participants, sponsored by PYC Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
- 6
- Study locations
Study Summary
This is a Phase 1/2 repeat-dose, open-label, two-arm, parallel group safety and efficacy study of two doses of VP-001 (30 μg and 75 μg) in participants with confirmed PRPF31 mutation-associated retinal dystrophy, including participants previously treated with VP001 in the PLATYPUS Study or WALLABY Study for a minimum of 8 weeks.
Conditions Studied
Interventions
- DRUG VP-001
Study Locations (6)
Florida
- University of Florida College of Medicine - Jacksonville
- Bascom Palmer Eye Institute - University of Miami - Miami
Texas
- Retina Foundation of the Southwest - Dallas
- Baylor College of Medicine - Houston
Michigan
- Kellogg Eye Center - University of Michigan - Ann Arbor
Oregon
- Casey Eye Institute - OHSU - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-06-01 |
| Est. Completion | 2028-03-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06852963
The ClinicalTrials.gov registry entry for NCT06852963 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,240-participant average among 19 other Retinal Disease trials with a reported enrollment target (99% lower). The listed sponsor is PYC Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Retinal Disease appearing as the primary indexed condition, and to 1 intervention - of which VP-001 is the first listed.
NCT06852963 reports 6 study locations spanning 4 distinct geographic areas - top geographies include Florida, Texas, Michigan.
Frequently Asked Questions
What is clinical trial NCT06852963 about?
NCT06852963 is a clinical study titled "A Repeat-Dose, Open-Label, Two Arm Safety and Efficacy Study of Two Doses of VP-001 Administered Intravitreally in Participants With Confirmed PRPF31 Mutation-Associated Retinal Dystrophy, Including Participants Previously Treated With VP001". This is a Phase 1/2 repeat-dose, open-label, two-arm, parallel group safety and efficacy study of two doses of VP-001 (30 μg and 75 μg) in participants with confirmed PRPF31 mutation-associated retinal dystrophy, including participants previously treated with VP001 in the PLATYPUS Study or WALLABY S...
What is the current status of trial NCT06852963?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-06-01. Estimated completion is 2028-03-03.
What conditions does trial NCT06852963 study?
This clinical trial studies the following conditions: Retinal Disease, Retinal Degeneration, Eye Diseases, Hereditary, Retinal Dystrophies, Retinitis Pigmentosa 11.
What interventions are being tested in trial NCT06852963?
The interventions under investigation include: VP-001 (DRUG).
Who is sponsoring clinical trial NCT06852963?
This trial is sponsored by PYC Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06852963 being conducted?
This trial has 6 study locations across Florida, Michigan, Oregon, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Retinal Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
MAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects (Wallaby)
RECRUITING · Phase 1
-
A Study to Evaluate the Safety and Tolerability of QR-1123 in Subjects With Autosomal Dominant Retinitis Pigmentosa Due to the P23H Mutation in the RHO Gene
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
RECRUITING · Phase 3
-
Genotype-Phenotype Study of Patients With Plaquenil -Induced Retinal Toxicity, With Evaluation of the ABCA4 Gene
RECRUITING
-
COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Inherited Retinal Disease
RECRUITING · NA
-
P200TxE Diseased Eye Image Collection
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.